Remove Bioinformatics Remove Disease Remove Laboratories
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.

RNA 59
article thumbnail

Vitamin A and its role in psychiatric and other disorders

Drug Target Review

In other words, a disease state may cause a change in vitamin A levels rather than the vitamin A levels causing a change in disease state. Again, in this circumstance adding the vitamin will not help therapeutically with the disease state. Secondly, it’s difficult to separate causation from reverse causation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Case study: NCI’s Molecular Targets Platform

The Open Targets Blog

The CCDI Molecular Targets Platform (MTP) is a collaborative effort between the Children’s Hospital of Philadelphia and the Frederick National Laboratory with input from the NCI and the U.S. Data integration under common ontological terms will aid in categorising diseases, genes, and agents. Food and Drug Administration (FDA).

article thumbnail

Can Global Genomic Surveillance Forecast the Next Pandemic?

PLOS: DNA Science

That’s thanks to accelerated genome sequencing technologies, expanded laboratory capabilities, and interacting infrastructure on a global level. Had we grown complacent in a world freed from a list of once-deadly infectious diseases, thanks largely to vaccines and other public health measures? COVID clearly caught us off guard.

Virus 98
article thumbnail

Malaria unravelled: decoding the parasite’s gene expression control

Drug Target Review

The study suggests that this regulatory system could be a potential target for future malaria treatments, offering hope for combatting this deadly disease that affects millions worldwide. The first identification was based on a bioinformatic analysis.

RNA 98
article thumbnail

Defense-Forward Biosecurity

Codon

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. At least nine laboratories outside the U.S. At least nine laboratories outside the U.S.

DNA 97
article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.